Adisseo(600299)2025-01-27 10:05Financial Performance - The company expects a net profit attributable to shareholders of RMB 1.204 billion for 2024, an increase of RMB 1.152 billion, representing a year-on-year growth of 2208.04%[3] - The net profit excluding non-recurring gains and losses is projected to be RMB 1.346 billion, up by RMB 1.333 billion, reflecting a year-on-year increase of 10256.90%[3] - Revenue is anticipated to grow by 18% to RMB 15.53 billion, with gross profit increasing by 67% to RMB 4.69 billion, resulting in a gross margin improvement of 9 percentage points to 30%[5] - The EBITDA margin excluding non-recurring gains and losses is expected to rise to 22%, an increase of 8 percentage points from 14% in 2023[7] Sales and Market Growth - The company achieved a strong sales growth of 24% in methionine, with both liquid and solid methionine products reaching historical sales highs[6] - The company continues to expand its market presence in China and Southeast Asia, particularly through the joint venture with Calysta, focusing on innovative protein solutions[6] Cost Management - The company has successfully reduced regular operating costs by RMB 179 million in 2024, contributing to improved cost efficiency[6] - The company has achieved a significant reduction in costs exceeding RMB 1 billion over the past six years, enhancing its competitive cost structure[7] Cash Flow and Financial Position - Cash balance as of December 31, 2024, is projected to be RMB 1.266 billion, an increase of RMB 260 million compared to December 31, 2023[7] Performance Forecast - The company emphasizes that the performance forecast is preliminary and subject to final audited results in the annual report[8]